Antidepressant effect in older depressed ...
Document type :
Article dans une revue scientifique
PMID :
Permalink :
Title :
Antidepressant effect in older depressed patients: the lessons of two agomelatine trials
Author(s) :
Goodwin, Guy M. [Auteur]
Thomas, Pierre [Auteur]
Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 [SCALab]
Sciences Cognitives et Sciences Affectives (SCALab) - UMR 9193
Heun, Reinhard [Auteur]
Boyer, Patrice [Auteur]
Picarel-Blanchot, Françoise [Auteur]
de Bodinat, Christian [Auteur]
Thomas, Pierre [Auteur]
Laboratoire Sciences Cognitives et Sciences Affectives - UMR 9193 [SCALab]
Sciences Cognitives et Sciences Affectives (SCALab) - UMR 9193
Heun, Reinhard [Auteur]
Boyer, Patrice [Auteur]
Picarel-Blanchot, Françoise [Auteur]
de Bodinat, Christian [Auteur]
Journal title :
International Clinical Psychopharmacology
Abbreviated title :
Int Clin Psychopharmacol
Volume number :
32
Pages :
184-194
Publication date :
2017-07
ISSN :
1473-5857
HAL domain(s) :
Sciences cognitives
English abstract : [en]
The present paper reports in parallel the findings of the two phase III trials that evaluated the efficacy of agomelatine in older depressed patients. It describes how the particular methodological innovations (particularly ...
Show more >The present paper reports in parallel the findings of the two phase III trials that evaluated the efficacy of agomelatine in older depressed patients. It describes how the particular methodological innovations (particularly in relation to patient selection, design and accuracy of diagnosis of depression) introduced in study 2 have improved the quality of recruitment of patients and the assay sensitivity. Study 1 lacked assay sensitivity, and among the many differences with study 2, the inclusion of unexpected mildly ill patients could have inflated the placebo response. The increased demands on investigators in study 2 appear to have reduced the placebo effect and showed a robust benefit of agomelatine. The two agomelatine studies offer the opportunity to discuss hypotheses that have been raised to explain the low level of response of older patients to available antidepressants.Show less >
Show more >The present paper reports in parallel the findings of the two phase III trials that evaluated the efficacy of agomelatine in older depressed patients. It describes how the particular methodological innovations (particularly in relation to patient selection, design and accuracy of diagnosis of depression) introduced in study 2 have improved the quality of recruitment of patients and the assay sensitivity. Study 1 lacked assay sensitivity, and among the many differences with study 2, the inclusion of unexpected mildly ill patients could have inflated the placebo response. The increased demands on investigators in study 2 appear to have reduced the placebo effect and showed a robust benefit of agomelatine. The two agomelatine studies offer the opportunity to discuss hypotheses that have been raised to explain the low level of response of older patients to available antidepressants.Show less >
Language :
Anglais
Audience :
Non spécifiée
Administrative institution(s) :
Université de Lille
CNRS
CHU Lille
CNRS
CHU Lille
Research team(s) :
Équipe Psychiatrie & Croyance (PsyCHIC)
Submission date :
2019-02-13T14:21:40Z
2019-11-06T11:47:02Z
2019-11-06T11:47:02Z